DNA Synthesizer Market To Generate $686.1 Million Revenue by 2030

The global DNA synthesizer market revenue is expected to reach USD 686.1 million by 2030, exhibiting a CAGR of 14.6% during 2024–2030. This can be ascribed to the growing research and development activities, rising consumer demand for more-personalized and efficacious treatments, strategic initiatives by the top players, and technological advancements in the sector.

There has been an increase in research activities to come up with more-advanced ways of synthesizing DNA that are not only affordable but also accurate. Such research has given rise to technologically advanced DNA synthesizers, which provide scientists across the world with independent and illimitable access to crucial life sciences tools. For instance, the DNA and RNA synthesizer of Austria-based company Kilobaser is incorporated with the chip and cartridge technology, which allows unskilled personnel to complete the synthesis of both the DNA as well as RNA in less time.

Overall, there has been a surge in research and development programs in the biotechnology industry across the world in the recent past, driven by the rising investments. Moreover, a large number of top industry players are moving their focus toward the expansion of their product portfolios by innovating more-cutting-edge synthesizers.

Moreover, companies are increasingly engaging in strategic activities, such as product launches, which will further propel the market growth. For instance, in June 2021, DNA Script announced the introduction of the SYNTAX system, which is a benchtop DNA printer powered by the enzymatic synthesis technology. The automated platform helps in accelerating genomics and molecular biology workflows.

Furthermore, in September 2022, Codex DNA Inc. announced the commercial launch of its next-generation automated synthetic biology workstation, BioXp 9600, which is a high-throughput benchtop equipment for synthetic biology workflows. The platform enables researchers to overcome the operational limitations inherent in the high complexity, price, and turnaround time of alternate means of gaining or developing mRNA and DNA.

Pilot Category Dominates Scale Segment

On the basis of scale, the pilot category leads the market with a share of 70% in 2023. This is owing to the advantages of pilot-scale DNA synthesizers, including easy measurement of the project quality by examining the features of the project and process, without worrying about a significant financial loss. These variants also aid in reducing test durations via the rapid and efficient identification of issues when handling mission-critical production environments, as well as allowing for the prevention as well as elimination of risks before the large-scale synthesis of the product.

The significant rise in the prevalence of all kinds of illnesses has led to an increase in the demand for biologics, such as vaccines, across the world, which, in turn, has led a large number of biotechnology firms to focus on their development. Such products need to be tested on the pilot scale before moving on to large-scale production, so that issues can be identified in the early stage itself and eliminated or solved easily and affordably, rather than after the official launch, which can lead to product recalls and significant economic losses for companies.

Asia-Pacific To Display Fastest Growth during Forecast Period

On the basis of regional analysis, Asia-Pacific is expected to progress with the highest CAGR, of 15.2%, during the forecast period. This is because of the rising support from the government for drug discovery and biologics research. Moreover, the rising demand for the continuous supply of synthetic DNA for research activities is propelling the market growth in the region. The large number of ongoing research studies, growing incidence of chronic ailments, and rapid emergence of new players in the sector are the major contributors to the market growth.

Key players in the market include Kilobaser GmbH, CSBio, Biolytic Lab Performance Inc., LGC Limited, Beckman Coulter Inc., and DNA Script.